In the current article we summarize the 15-year experience of the Spanish Cell Therapy Network (TerCel), a successful collaborative public initiative funded by the Spanish government for the support of nationwide translational research in this important area. Thirty-two research groups organized in three programs devoted to cardiovascular, neurodegenerative and immune-inflammatory diseases, respectively, currently form the network. Each program has three working packages focused on basic science, pre-clinical studies and clinical application. TerCel has contributed during this period to boost the translational research in cell therapy in Spain, setting up a network of Good Manufacturing Practice-certified cell manufacturing facilities- and increasing the number of translational research projects, publications, patents and clinical trials of the participating groups, especially those in collaboration. TerCel pays particular attention to the public-private collaboration, which, for instance, has led to the development of the first allogeneic cell therapy product approved by the European Medicines Agency, Darvadstrocel. The current collaborative work is focused on the development of multicenter phase 2 and 3 trials that could translate these therapies to clinical practice for the benefit of patients.

中文翻译：

---

西班牙细胞治疗网络 (TerCel)：15 年成功的合作转化研究

在本文中，我们总结了西班牙细胞治疗网络 (TerCel) 15 年的经验，这是一项由西班牙政府资助的成功合作公共倡议，用于支持这一重要领域的全国性转化研究。目前，该网络由 32 个研究小组组成，分为三个项目，分别致力于心血管疾病、神经退行性疾病和免疫炎症疾病。每个项目都有三个工作包，重点是基础科学、临床前研究和临床应用。TerCel 在此期间为促进西班牙细胞治疗的转化研究做出了贡献，建立了良好生产规范认证的细胞制造设施网络，并增加了转化研究项目、出版物、参与团体的专利和临床试验，特别是合作团体的专利和临床试验。TerCel 特别关注公私合作，例如，这导致了第一个获得欧洲药品管理局批准的同种异体细胞治疗产品 Darvadstrocel 的开发。目前的合作工作重点是开发多中心 2 和 3 期试验，这些试验可以将这些疗法转化为临床实践，以造福患者。